ADVERTISEMENT
ADVERTISEMENT

Dr Reddy’s plant under USFDA lens

Dr Reddy’s plant under USFDA lens
Highlights

City-based pharma major Dr Reddy’s Laboratories has received four observations from US health regulator after inspecting its active pharmaceutical ingredients (API) facility in Jinnaram Mandal, Medak district.

Hyderabad: City-based pharma major Dr Reddy’s Laboratories has received four observations from US health regulator after inspecting its active pharmaceutical ingredients (API) facility in Jinnaram Mandal, Medak district.

In a statement, Dr Reddy’s Lab said: “The audit of our API Hyderabad plant-1 in Jinnaram Mandal, Medak district, by the USFDA has been completed. We have been issued a Form 483 with four observations which will be addressed comprehensively within stipulated time.”

As per the USFDA, a Form 483 is issued to a firm's management at the conclusion of an inspection when investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. It notifies the company's management of objectionable conditions. Dr Reddy's shares closed down by Rs 45.10 or 2.07 per cent at Rs 2,138.10 on BSE.

Show Full Article
Download The Hans India Android App or iOS App for the Latest update on your phone.
Subscribed Failed...
Subscribed Successfully...
More Stories


Top